Investor Presentation

Here is the financial summary for RPG Life Sciences: **Business Performance:** RPG Life Sciences delivered robust Q4 FY26, with revenue jumping 23.6% to 176.9 Cr and PAT (excluding exceptional items) soaring 58.1% to 29.3 Cr.

For FY26, revenue grew 8.3% to 707.5 Cr.

Domestic Formulations led performance, up 13.7% for the year, consistently outperforming the Indian Pharma Market (IPM) by 1.6x. API sales, however, saw a 6.7% dip following a manufacturing block incident. **Recent Developments:** The company's ICRA rating was reaffirmed at A+ with a stable outlook, highlighting a robust, debt-free capital structure. **Growth Drivers & Outlook:** Strategically, RPG Life Sciences aims to scale core brands like Naprosyn to over 100 Cr and grow its immunosuppressant portfolio beyond 200 Cr.

Future plans include expanding specialty/chronic segments with new launches, strengthening API business globally, and leveraging digital initiatives.

A 140 Cr capex infusion since FY22 supports modern plant facilities and ongoing productivity enhancements.